HK1014013A1 - Interleukin 1-beta protease and interleukin 1-betaprotease inhibitors. - Google Patents
Interleukin 1-beta protease and interleukin 1-betaprotease inhibitors.Info
- Publication number
- HK1014013A1 HK1014013A1 HK98115247A HK98115247A HK1014013A1 HK 1014013 A1 HK1014013 A1 HK 1014013A1 HK 98115247 A HK98115247 A HK 98115247A HK 98115247 A HK98115247 A HK 98115247A HK 1014013 A1 HK1014013 A1 HK 1014013A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- interleukin
- asp
- amino acid
- beta
- protease
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/81—Protease inhibitors
- C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
- C07K14/8142—Aspartate protease (E.C. 3.4.23) inhibitors, e.g. HIV protease inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
- C07C271/06—Esters of carbamic acids
- C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
- C07C271/10—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C271/22—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of hydrocarbon radicals substituted by carboxyl groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/545—IL-1
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
- C07K5/0202—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-X-X-C(=0)-, X being an optionally substituted carbon atom or a heteroatom, e.g. beta-amino acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06191—Dipeptides containing heteroatoms different from O, S, or N
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6472—Cysteine endopeptidases (3.4.22)
- C12N9/6475—Interleukin 1-beta convertase-like enzymes (3.4.22.10; 3.4.22.36; 3.4.22.63)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
- Y10S530/868—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof involving autoimmunity, allergy, immediate hypersensitivity, delayed hypersensitivity, immunosuppression, or immunotolerance
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biomedical Technology (AREA)
- Gastroenterology & Hepatology (AREA)
- Crystallography & Structural Chemistry (AREA)
- AIDS & HIV (AREA)
- Toxicology (AREA)
- Rheumatology (AREA)
- Immunology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- General Engineering & Computer Science (AREA)
- Dermatology (AREA)
- Obesity (AREA)
- Pain & Pain Management (AREA)
- Nutrition Science (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US75064491A | 1991-08-30 | 1991-08-30 | |
PCT/US1991/006595 WO1993005071A1 (en) | 1991-08-30 | 1991-09-12 | INTERLEUKIN 1β PROTEASE AND INTERLEUKIN 1β PROTEASE INHIBITORS |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1014013A1 true HK1014013A1 (en) | 1999-09-17 |
Family
ID=25018683
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK98115247A HK1014013A1 (en) | 1991-08-30 | 1998-12-23 | Interleukin 1-beta protease and interleukin 1-betaprotease inhibitors. |
Country Status (22)
Country | Link |
---|---|
US (2) | US5756465A (xx) |
EP (2) | EP1378573A1 (xx) |
JP (3) | JP2759895B2 (xx) |
KR (1) | KR100226296B1 (xx) |
AT (1) | ATE257517T1 (xx) |
AU (1) | AU657701B2 (xx) |
CA (1) | CA2111100C (xx) |
DE (1) | DE69133354T2 (xx) |
DK (1) | DK0600880T3 (xx) |
ES (1) | ES2213138T3 (xx) |
FI (1) | FI935020A (xx) |
HK (1) | HK1014013A1 (xx) |
HU (1) | HU220098B (xx) |
IE (1) | IE913268A1 (xx) |
IL (2) | IL99598A (xx) |
MX (1) | MX9101346A (xx) |
MY (1) | MY131144A (xx) |
NO (1) | NO317129B1 (xx) |
NZ (3) | NZ335312A (xx) |
PT (1) | PT99118B (xx) |
RU (2) | RU2206611C2 (xx) |
WO (1) | WO1993005071A1 (xx) |
Families Citing this family (52)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5874424A (en) * | 1995-12-20 | 1999-02-23 | Vertex Pharmaceuticals Incorporated | Inhibitors of interleukin-1β converting enzyme |
US6204261B1 (en) | 1995-12-20 | 2001-03-20 | Vertex Pharmaceuticals Incorporated | Inhibitors of interleukin-1β Converting enzyme inhibitors |
US6008217A (en) * | 1995-12-20 | 1999-12-28 | Vertex Pharmaceuticals Incorporated | Inhibitors of interleukin-1β converting enzyme |
US6995141B1 (en) | 1990-04-04 | 2006-02-07 | Vertex Pharmaceuticals Incorporated | Interleukin 1β protease and interleukin 1β protease inhibitors |
RU2206611C2 (ru) * | 1991-08-30 | 2003-06-20 | Вертекс Фармасьютикалз Инкорпорейтед | ФРАГМЕНТ ДНК, ПЛАЗМИДНЫЙ ВЕКТОР, СПОСОБ ПОЛУЧЕНИЯ ПОЛИПЕПТИДА И ПОЛИПЕПТИД, ОБЛАДАЮЩИЙ IL-1β ПРОТЕАЗНОЙ АКТИВНОСТЬЮ |
IL105741A0 (en) * | 1992-05-22 | 1993-09-22 | Genta Inc | Pharmaceutical compositions for treating cellular hyperproliferation using interleukin-1 inhibitory compounds |
US5462939A (en) * | 1993-05-07 | 1995-10-31 | Sterling Winthrop Inc. | Peptidic ketones as interleukin-1β-converting enzyme inhibitors |
JPH0789951A (ja) * | 1993-06-03 | 1995-04-04 | Sterling Winthrop Inc | インターロイキン−1β転換酵素阻害剤 |
US5843905A (en) * | 1993-06-04 | 1998-12-01 | Vertex Pharmaceuticals, Incorporated | Peptidic phosphinyloxymethyl ketones as interleukin-1β-converting enzyme inhibitors |
ES2122145T3 (es) * | 1993-06-04 | 1998-12-16 | Vertex Pharma | Fosfiniloximetil-cetonas peptidicas como inhibidores de la enzima convertida de la interleuquina-1 beta. |
JPH08511690A (ja) * | 1993-06-24 | 1996-12-10 | ザ・ジェネラル・ホスピタル・コーポレーション | プログラムされた細胞死遺伝子及びタンパク質 |
US6087160A (en) * | 1993-06-24 | 2000-07-11 | The General Hospital Corporation | Programmed cell death genes and proteins |
US5756466A (en) * | 1994-06-17 | 1998-05-26 | Vertex Pharmaceuticals, Inc. | Inhibitors of interleukin-1β converting enzyme |
US6420522B1 (en) | 1995-06-05 | 2002-07-16 | Vertex Pharmaceuticals Incorporated | Inhibitors of interleukin-1β converting enzyme |
US5847135A (en) * | 1994-06-17 | 1998-12-08 | Vertex Pharmaceuticals, Incorporated | Inhibitors of interleukin-1β converting enzyme |
US5716929A (en) * | 1994-06-17 | 1998-02-10 | Vertex Pharmaceuticals, Inc. | Inhibitors of interleukin-1β converting enzyme |
US5955072A (en) * | 1994-07-13 | 1999-09-21 | Sankyo Company, Limited | Expression systems utilizing autolyzing fusion proteins and a reducing polypeptide |
WO1996012025A1 (en) * | 1994-10-14 | 1996-04-25 | Basf Aktiengesellschaft | TRANSGENIC NONHUMAN ANIMAL HAVING FUNCTIONALLY DISRUPTED INTERLEUKIN-1β CONVERTING ENZYME GENE |
AU5122196A (en) * | 1995-03-31 | 1996-10-16 | Takeda Chemical Industries Ltd. | Cysteine protease inhibitor |
US5869315A (en) | 1995-12-18 | 1999-02-09 | Basf Aktiengesellschaft | Modified interleukin-1β converting enzyme with increased stability |
US5843904A (en) * | 1995-12-20 | 1998-12-01 | Vertex Pharmaceuticals, Inc. | Inhibitors of interleukin-1βconverting enzyme |
US6288037B1 (en) | 1996-01-29 | 2001-09-11 | Basf Aktiengesellschaft | Substrates and inhibitors for cysteine protease ICH-1 |
US6416753B1 (en) | 1996-03-15 | 2002-07-09 | The General Hospital Corporation | Method for modulating apoptosis |
US6610683B2 (en) | 1996-09-12 | 2003-08-26 | Idun Pharmaceuticals, Inc. | Treatment of infectious disease using interleukin-1β-converting enzyme (ICE)/CED-3 family inhibitors |
US6200969B1 (en) | 1996-09-12 | 2001-03-13 | Idun Pharmaceuticals, Inc. | Inhibition of apoptosis using interleukin-1β-converting enzyme (ICE)/CED-3 family inhibitors |
US6531467B2 (en) | 1996-09-12 | 2003-03-11 | Idun Pharmaceuticals, Inc. | Inhibition of inflammation using interleukin-1β-converting enzyme (ICE)/CED-3 family inhibitors |
US6184244B1 (en) | 1996-12-16 | 2001-02-06 | Idun Pharmaceuticals, Inc. | C-terminal modified (N-substituted)-2-indolyl dipeptides as inhibitors of the ICE/ced-3 family of cysteine proteases |
US6054487A (en) * | 1997-03-18 | 2000-04-25 | Basf Aktiengesellschaft | Methods and compositions for modulating responsiveness to corticosteroids |
US6184210B1 (en) | 1997-10-10 | 2001-02-06 | Cytovia, Inc. | Dipeptide apoptosis inhibitors and the use thereof |
KR100580333B1 (ko) * | 1997-10-10 | 2006-05-16 | 시토비아 인크. | 디펩티드 고사 억제제 및 그의 용도 |
ES2244178T3 (es) | 1998-03-09 | 2005-12-01 | Vertex Pharmaceuticals Incorporated | Derivados de 1,2-diazepan como inhibidores de la enzima convertidora de interleuquina-1 beta. |
EP1076563B1 (en) * | 1998-03-16 | 2005-05-11 | Cytovia, Inc. | Dipeptide caspase inhibitors and the use thereof |
KR100898094B1 (ko) | 1998-03-19 | 2009-05-18 | 버텍스 파마슈티칼스 인코포레이티드 | 카스파제의 억제제 |
DE60030097T2 (de) * | 1999-03-16 | 2007-03-08 | Cytovia, Inc., San Diego | Substituierte 2-aminobenzamin caspase inhibitoren und ihre verwendung |
DE19915465A1 (de) * | 1999-04-06 | 2000-10-19 | Apotech Res & Dev Ltd | Verwendung eines Caspase-Inhibitors zur Proliferationshemmung von Zellen und Verwendung eines oder mehrerer Caspase-Inhibitors/en zur Behandlung von Erkrankungen beruhend auf Lymphozyten-Hyperproliferation oder zur Suppression einer Immunantwort durch Lymphozyten |
MXPA01010127A (es) | 1999-04-09 | 2002-08-20 | Cytovia Inc | Inhibidores de la caspasa y el uso de los mismos. |
IL146923A0 (en) * | 1999-06-14 | 2002-08-14 | Wisconsin Alumni Res Found | Oligomers and polymers of cyclic imino carboxylic acids |
CN1235875C (zh) | 1999-08-27 | 2006-01-11 | 西托维亚公司 | 取代的α-羟基酸天冬氨酸特异性半胱氨酸蛋白酶抑制剂及其用途 |
US6566338B1 (en) | 1999-10-12 | 2003-05-20 | Cytovia, Inc. | Caspase inhibitors for the treatment and prevention of chemotherapy and radiation therapy induced cell death |
SI1268425T1 (sl) | 2000-03-29 | 2008-04-30 | Vertex Pharma | Zaviralci karbamat kaspaze in uporaba le-teh |
ATE384695T1 (de) | 2000-03-29 | 2008-02-15 | Vertex Pharma | Carbamat caspase inhibitoren und deren verwendung |
AU2001259758A1 (en) * | 2000-05-12 | 2001-11-26 | Immunex Corporation | Interleukin-1 inhibitors in the treatment of diseases |
PE20011350A1 (es) | 2000-05-19 | 2002-01-15 | Vertex Pharma | PROFARMACO DE UN INHIBIDOR DE ENZIMA CONVERTIDORA DE INTERLEUCINA-1ß (ICE) |
EA006860B1 (ru) * | 2002-01-29 | 2006-04-28 | Уайт | Композиции и способы модулирования гемиканалов коннексина |
CA2484959A1 (en) | 2002-04-30 | 2003-11-13 | Yungjin Pharmaceutical Co., Ltd. | Quinoline derivatives as caspase-3 inhibitor, preparation for producing the same and pharmaceutical composition comprising the same |
AU2004275821A1 (en) * | 2003-09-25 | 2005-04-07 | Dmi Biosciences Inc. | Methods and products which utilize N-acyl-L-aspartic acid |
WO2005115362A1 (en) | 2004-05-15 | 2005-12-08 | Vertex Pharmaceuticals Incorporated | Treating seizures using ice inhibitors |
GB0411056D0 (en) | 2004-05-18 | 2004-06-23 | Novartis Ag | Organic compounds |
CA2567080A1 (en) | 2004-05-27 | 2005-12-15 | Vertex Pharmaceuticals Incorporated | Ice inhibitors for the treatment of autoinflammatory diseases |
US7618801B2 (en) * | 2007-10-30 | 2009-11-17 | Danison US Inc. | Streptomyces protease |
US20140309172A1 (en) | 2010-11-05 | 2014-10-16 | Dagmar Ringe | Ice inhibiting compounds and uses thereof |
US9956260B1 (en) | 2011-07-22 | 2018-05-01 | The J. David Gladstone Institutes | Treatment of HIV-1 infection and AIDS |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1984000365A1 (en) * | 1982-07-19 | 1984-02-02 | Nat Res Dev | Synthetic peptides and their preparation |
US4636492A (en) * | 1984-08-29 | 1987-01-13 | E. I. Du Pont De Nemours And Company | Inhibition of viral protease activity by peptide halomethyl ketones |
US5104853A (en) * | 1984-12-11 | 1992-04-14 | California Biotechnology Inc. | Alveolar surfactant proteins having cys to ser mutations |
JPS63145300A (ja) * | 1984-12-17 | 1988-06-17 | イ−・アイ・デユポン・デ・ニモアス・アンド・カンパニ− | ウイルスにより特定されているプロテア−ゼの特異的阻害剤を製造する方法 |
US4644055A (en) * | 1984-12-17 | 1987-02-17 | E. I. Du Pont De Nemours And Company | Method for preparing specific inhibitors of virus-specified proteases |
US5225354A (en) * | 1986-08-22 | 1993-07-06 | Molecular Diagnostics, Inc. | Monoclonal antibodies specific for human glycoalbumin |
WO1991000912A1 (en) * | 1989-07-07 | 1991-01-24 | Massachusetts Institute Of Technology | Production and use of hybrid protease inhibitors |
WO1991015577A1 (en) * | 1990-04-04 | 1991-10-17 | Black, Roy, A. | INTERLEUKIN 1'beta' PROTEASE |
US5298421A (en) * | 1990-04-26 | 1994-03-29 | Calgene, Inc. | Plant medium-chain-preferring acyl-ACP thioesterases and related methods |
EP0533350B1 (en) * | 1991-08-16 | 1999-05-26 | Merck & Co. Inc. | DNA encoding precursor interleukin 1B converting enzyme |
RU2206611C2 (ru) * | 1991-08-30 | 2003-06-20 | Вертекс Фармасьютикалз Инкорпорейтед | ФРАГМЕНТ ДНК, ПЛАЗМИДНЫЙ ВЕКТОР, СПОСОБ ПОЛУЧЕНИЯ ПОЛИПЕПТИДА И ПОЛИПЕПТИД, ОБЛАДАЮЩИЙ IL-1β ПРОТЕАЗНОЙ АКТИВНОСТЬЮ |
-
1991
- 1991-09-12 RU RU94028712/13A patent/RU2206611C2/ru not_active IP Right Cessation
- 1991-09-12 JP JP3515380A patent/JP2759895B2/ja not_active Expired - Lifetime
- 1991-09-12 EP EP03018990A patent/EP1378573A1/en not_active Withdrawn
- 1991-09-12 EP EP91916780A patent/EP0600880B1/en not_active Expired - Lifetime
- 1991-09-12 CA CA002111100A patent/CA2111100C/en not_active Expired - Lifetime
- 1991-09-12 KR KR1019940700644A patent/KR100226296B1/ko not_active IP Right Cessation
- 1991-09-12 DK DK91916780T patent/DK0600880T3/da active
- 1991-09-12 HU HU9303244A patent/HU220098B/hu not_active IP Right Cessation
- 1991-09-12 AU AU85373/91A patent/AU657701B2/en not_active Expired
- 1991-09-12 ES ES91916780T patent/ES2213138T3/es not_active Expired - Lifetime
- 1991-09-12 DE DE69133354T patent/DE69133354T2/de not_active Expired - Lifetime
- 1991-09-12 AT AT91916780T patent/ATE257517T1/de not_active IP Right Cessation
- 1991-09-12 WO PCT/US1991/006595 patent/WO1993005071A1/en active IP Right Grant
- 1991-09-16 IE IE326891A patent/IE913268A1/en not_active IP Right Cessation
- 1991-09-18 MY MYPI91001693A patent/MY131144A/en unknown
- 1991-09-23 NZ NZ335312A patent/NZ335312A/en not_active IP Right Cessation
- 1991-09-23 NZ NZ248377A patent/NZ248377A/xx not_active IP Right Cessation
- 1991-09-23 NZ NZ239895A patent/NZ239895A/en not_active IP Right Cessation
- 1991-09-27 IL IL9959891A patent/IL99598A/xx not_active IP Right Cessation
- 1991-09-30 MX MX9101346A patent/MX9101346A/es not_active IP Right Cessation
- 1991-09-30 PT PT99118A patent/PT99118B/pt not_active IP Right Cessation
-
1993
- 1993-11-12 FI FI935020A patent/FI935020A/fi not_active Application Discontinuation
- 1993-11-30 NO NO19934335A patent/NO317129B1/no unknown
-
1995
- 1995-05-12 US US08/440,179 patent/US5756465A/en not_active Expired - Lifetime
-
1997
- 1997-03-03 JP JP9061701A patent/JPH1028588A/ja active Pending
-
1998
- 1998-03-16 US US09/039,657 patent/US6136787A/en not_active Expired - Lifetime
- 1998-12-23 HK HK98115247A patent/HK1014013A1/xx not_active IP Right Cessation
-
2000
- 2000-11-09 JP JP2000342474A patent/JP3445572B2/ja not_active Expired - Lifetime
-
2002
- 2002-10-25 RU RU2002128757/13A patent/RU2002128757A/ru not_active Application Discontinuation
-
2005
- 2005-02-09 IL IL16679105A patent/IL166791A0/xx unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1014013A1 (en) | Interleukin 1-beta protease and interleukin 1-betaprotease inhibitors. | |
AU617875B2 (en) | Novel peptidase inhibitors | |
ES8800050A1 (es) | Un procedimiento para la preparacion de derivados de cetona electrofilicos activados de sustratos de peptidasa, utiles en la inhibicion de enzimas proteasas | |
KR900017607A (ko) | 프로테이나아제 억제제, 이것의 제조방법 및 이들을 함유한 의약품 | |
AU4799793A (en) | Beta -aminoalkyl and beta -n-peptidylaminoalkyl boronic acids | |
GR860398B (en) | Process for obtaining peptidic derivatives of renine inhibitors and proteases acids | |
EP0202853A3 (en) | A polypeptide which neutralises the activity of factor viii inhibitor and a therapeutic composition containing it | |
EP0187721A3 (en) | Preparation of peptide substrates for virus-specified proteases | |
HUP0101899A2 (hu) | Cisztein-aktivitástól függő enzimeket gátló hatású tiadiazolvegyületek, azokat tartalmazó gyógyszerkészítmények és alkalmazásuk | |
LV10108A (lv) | Sunu proliferacijas inhibitori farmaceitiska kompozicija savienojumu iegusanas metode sunu proliferacijas inhibesanas panemieni | |
AU5232886A (en) | Serine protease inhibitors and methods for isolation of same | |
DK0561877T3 (da) | Forbindelser og præparater der hæmmer knogleresorption | |
ES2089177T3 (es) | Nuevos peptidos inhibidores. | |
EP0352816A3 (en) | Il-1alpha derivates and medicament for treating thrombocytopenia | |
NO893507L (no) | Fremgangsmaate for fremstilling av nye peptidaseinhibitorer | |
ES8607216A1 (es) | Procedimiento de preparacion de &-aspartil peptidos | |
Song | Synthesis of fluorinated and phosphono diaminopimelic acid (DAP) isomers as inhibitors of DAP enzymes |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PE | Patent expired |
Effective date: 20110911 |